DGX Quest: Net earnings per share for the last four quarters
The stability of the US domestic market ensures business predictability for Quest Diagnostics (DGX). The annual volatility of TTM net income per share captures this trend, with this metric equaling 17.80. Efficiency is driven by IT integration and network scale, although the reduction of government support and post-pandemic labor shortages are constraining profit dynamics.
DGX (questdiagnostics.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- debt and liquidity data:
Debt to Capital Quest Diagnostics|DGX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Quest Diagnostics Incorporated|DGX - Company Total Debt|Debt to Book Capital Quest Diagnostics|DGX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Quest Diagnostics|Immediate Liquidity Ratio questdiagnostics.com
- company profitability and valuation multiples indicators:
DGX - Net Profit|Company Profit Forecast Quest Diagnostics|DGX - P/E Multiple|Forward P/E Multiple Quest|DGX - PEG Multiple|Enterprise Value to EBITDA Multiple Quest Corp|DGX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Quest Diagnostics|DGX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months questdiagnostics.com|DGX - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Quest Diagnostics
- sales volume and revenue information:
Fundamental valuation:Quest (DGX)
Fundamental asset screening begins with an analysis of net income dynamics. The annual EPS TTM growth rate measures the percentage change in rolling earnings per share over a year, reflecting the efficiency of capital generation. Temporary dips in this indicator often signal modernization rather than stagnation. For Quest Diagnostics (DGX), such volatility is acceptable given the critical importance of its high-margin laboratory network to US healthcare.
Direct competitors
A - Net earnings per share (EPS TTM)|ILMN: Net earnings per share (EPS TTM)|EXAS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months revvity.com|Earnings per share for the last twelve months BIO|Net earnings per share (EPS TTM) NNNN|SHC - Net earnings per one share for the last twelve months|Quidel Corporation - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) OPKO Health Corp. OPK|CDNA - Earnings per share for the last twelve months|Earnings per share for the trailing year MRVI (Maravai LifeSciences)|FLGT: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months LAB|Earnings per share for the last twelve months Cytek Biosciences Inc|Net earnings per share (EPS TTM) OraSure Corp|Net earnings per share for the last 12 months XGN (Exagen Inc)|Net earnings per share (EPS TTM) mdxhealth.com (MDXH)|Net earnings per share (EPS TTM) LUCD (Lucid Diagnostics Inc)|PRE - Net earnings per share for the last 12 months|IMDX: Net earnings per share for the last 12 months|Earnings per share for the trailing year TRIB (trinitybiotech.com)|PRPH (ProPhase Labs, Inc.) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Ainos|Earnings per share for the last twelve months Co-Diagnostics Inc|HSCS (Heart Test Laboratories Inc.) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) BMRA|Cardio Diagnostics Holdings Inc. (CDIO) - Net earnings per share for the trailing year|Earnings per share for the last twelve months Onconetix ONCO|viraxbiolabs.com - Earnings per share for the last twelve months|BJDX - Earnings per share for the last twelve months|Earnings per share for the trailing year AWH (Aspira Women's Health Inc.)|AXDX: Net earnings per share (EPS TTM)|CNTG - Net earnings per share for the last four quarters|ENZ (enzo.com) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months FRES|Earnings per share for the last twelve months Genetic Technologies (GENE)|Net earnings per share for the last four quarters 23andMe Holding Co|Net earnings per share (EPS TTM) PMD (Psychemedics)
